Role of homocysteine in the treatment of Parkinson's disease
Author:
- 1 June 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 8 (6) , 957-967
Abstract
(2008). Role of homocysteine in the treatment of Parkinson's disease. Expert Review of Neurotherapeutics: Vol. 8, No. 6, pp. 957-967.Keywords
This publication has 117 references indexed in Scilit:
- Plasma Homocysteine Levels and Parkinson DiseaseClinical Neuropharmacology, 2006
- The transmethylation cycle in the brain of Alzheimer patientsNeuroscience Letters, 2005
- Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's diseaseLife Sciences, 2005
- Activation of catechol‐O‐methyltransferase in astrocytes stimulates homocysteine synthesis and export to neuronsGlia, 2005
- The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult ratsJournal of Neural Transmission, 2004
- Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's diseaseNeuroscience Letters, 2004
- Studies on homocysteine plasma levels in Alzheimer?s patients. Relevance for neurodegenerationJournal of Neural Transmission, 2004
- Plasma levels of R- and S-salsolinol are not increased in "de-novo" Parkinsonian patientsJournal of Neural Transmission, 1998
- DEPLETION OF NIGROSTRIATAL AND FOREBRAIN TYROSINE HYDROXYLASE BY S-ADENOSYLMETHIONINE: A MODEL THAT MAY EXPLAIN THE OCCURRENCE OF DEPRESSION IN PARKINSON'S DISEASELife Sciences, 1997
- Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders?Journal of Neural Transmission, 1993